Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2018-11-28 / Cancers (Basel) 2018 Nov;10(12)Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
/in Dendritic Cells, International Publications /von 2018-11-23 / Vaccines (Basel) 2018 Nov;6(4)Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth
/in Cervical Cancer, Hyperthermia, International Publications, Ovarian Cancer /von 2018-11-14 / Int J Hyperthermia 2019;36(1):9-20Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2018-11-14 / Clin Transl Med 2018 Nov;7(1):35The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
/in Dendritic Cells, Glioblastoma, International Publications /von 2018-11-12 / Cancers (Basel) 2018 Nov;10(11)First in vitro evidence of modulated electro-hyperthermia treatment performance in combination with megavoltage radiation by clonogenic assay
/in Hyperthermia, International Publications /von 2018-11-09 / Sci Rep 2018 Nov;8(1):16608Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia
/in Gastric Cancer, Hyperthermia, International Publications /von 2018-11-01 / Anticancer Res. 2018 Nov;38(11):6561-6564Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)
/in Dendritic Cells, International Publications, NSCLC /von 2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-728IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de